Search for content, post, videos

Novo Nordisk in million dollar settlement

Danish Novo Nordisk has reached a settlement with the American sales company Rocheset Drug regarding the diabetes substance Prandin.

Novo Nordisk has agreed to pay USD 19 million according to the agreement. The reason behind the disagreement is a lawsuit from Rocheset Drug in January 2014. The American sales company demanded compensation for lost sales revenues and claimed that Novo Nordisk had “abused” their patent on Prandin, which resulted in a delay of the market introduction of corresponding generics.